Zoetis Inc. (NYSE:ZTS) was the recipient of unusually large options trading activity on Wednesday. Traders bought 25,516 call options on the stock. This is an increase of approximately Infinity compared to the average volume of 0 call options.
Several hedge funds and other institutional investors have recently bought and sold shares of ZTS. Sii Investments Inc. WI raised its stake in shares of Zoetis by 0.3% during the 1st quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock worth $383,000 after acquiring an additional 23 shares in the last quarter. Highbridge Capital Management LLC bought a new position in shares of Zoetis during the 1st quarter worth approximately $10,764,000. Gotham Asset Management LLC bought a new position in shares of Zoetis during the 1st quarter worth approximately $3,682,000. BlueCrest Capital Management Ltd bought a new position in shares of Zoetis during the 1st quarter worth approximately $534,000. Finally, AQR Capital Management LLC raised its stake in shares of Zoetis by 13.6% during the 1st quarter. AQR Capital Management LLC now owns 105,747 shares of the company’s stock worth $5,644,000 after acquiring an additional 12,644 shares in the last quarter. Hedge funds and other institutional investors own 93.04% of the company’s stock.
Several research firms have commented on ZTS. Morgan Stanley lifted their target price on shares of Zoetis from $61.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Friday. BMO Capital Markets lifted their target price on shares of Zoetis from $65.00 to $70.00 and gave the stock a “market perform” rating in a research report on Friday. BidaskClub raised shares of Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 12th. Stifel Nicolaus reissued a “buy” rating and set a $65.00 target price on shares of Zoetis in a research report on Tuesday, October 24th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $75.00 target price on shares of Zoetis in a research report on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the stock. Zoetis has a consensus rating of “Buy” and an average target price of $67.06.
Shares of Zoetis (NYSE:ZTS) opened at $68.69 on Friday. The firm has a market capitalization of $32,799.38, a P/E ratio of 30.88, a P/E/G ratio of 2.01 and a beta of 1.02. The company has a debt-to-equity ratio of 2.13, a quick ratio of 1.17 and a current ratio of 2.01.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.63 by $0.02. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 66.15%. Zoetis’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.52 EPS. equities analysts predict that Zoetis will post 2.36 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be paid a dividend of $0.105 per share. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 annualized dividend and a dividend yield of 0.61%. Zoetis’s dividend payout ratio (DPR) is presently 22.11%.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
What are top analysts saying about Zoetis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zoetis Inc. and related companies.